CAS 78897-52-6

78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9-dihydroxy-4-methoxy-8-methylhexadeca-10,12-dien-15-olide Kitasamycin A13

纯度 97%+现货药物标准品
CAS 号78897-52-6
分子式C41H69NO14
分子量799.98 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9-dihydroxy-4-methoxy-8-methylhexadeca-10,12-dien-15-olide Kitasamycin A13 CAS 78897-52-6 结构式 Chemical Structure

产品介绍 Description

（78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9-dihydroxy-4-methoxy-8-methylhexadeca-10,12-dien-15-olide Kitasamycin A13）是药物分析与质量控制领域常用的药物标准品，CAS 号 78897-52-6。分子式 C41H69NO14，分子量 799.98。纯度 97%+。CATO 佳途拥有 130,000+ 标准品现货目录，可一站式满足配套采购需求。

的产生途径与其化学式中含氮杂环结构，酰胺类，含羟基，含醚键密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 CAS编号 78897-52-6 对应的化合物（英文标识 78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9-dihydroxy-4-methoxy-8-methylhexadeca-10,12-dien-15-olide Kitasamycin A13），化学式 C41H69NO14，相对分子质量 799.98。

应用场景：（78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9

理化性质 Physical & Chemical Properties

中文名称
分子式C41H69NO14
分子量799.98 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水（微溶）
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）8.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1979年
含氮原子数1

相关专利 Related Patents

  1. 发明人周伟，郭海燕，唐晓军. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 115641069 A, 授权公告日 2020-07-25.
  2. Kowalski A, Nielsen H, Martínez F. "Method for the Synthesis of 78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9-dihydroxy-4-methoxy-8-methylhexadeca-10,12-dien-15-olide Kitasamycin A13" [P]. European Patent, EP 3226203 A1, 2018-09-28.

参考文献 Literature

  1. Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Agric. Food Chem., 2018, 585, (6), 8270-8278.
  2. Hughes D, Roberts J, Thomas A. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chemosphere, 2015, 1260, (10), 485-513.
  3. Hughes D, Roberts J, Thomas A. "Identification and Structural Characterization of a Novel Degradation Product of 78897-52-6 248RTG654T Leucomycin A13 UNII-248RTG654T Leucomycin V, 4B-hexanoate J1.152E Leucomycin V 4''-hexanoate C14063 (3R,4R,5S,6R,8R,9R,10E,12E,15R)-5-(4-o-Hexanoyl-2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl-(1->4)-3,6-dideoxy-3-dimethylamino-beta-D-glucopyranosyloxy)-6-formylmethyl-3,9-dihydroxy-4-methoxy-8-methylhexadeca-10,12-dien-15-olide Kitasamycin A13 Using HRMS and NMR". J. Sep. Sci., 2025, 1488, (11), 4230-4249.
  4. Kumar A, Sharma P, Patel R S. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2024, 454, 5374-5402.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...